Liraglutide (Saxenda) vs Semaglutide (Wegovy)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
Liraglutide (Saxenda)
Marketed by Novo Nordisk
NCT00781937 · Phase 3 · completed
The trial randomly assigned 212 participants to liraglutide and 210 to placebo in a double-blind, placebo-controlled design, with objective body-weight outcomes assessed at week 56. All three prespecified primary comparisons favored liraglutide and were statistically significant (each p<0.0001), supporting a strong evidence grade.
Next expected readout: December 2026 · NCT07225816 (registry estimate)
Reported efficacy
Change in BMI SDS (Week 0, Week 56): Change in BMI SDS (Week 0, Week 56) (Week 0, week 56): Liraglutide 3.0 mg -0.25 SDS score (Standard Deviation 0.51) vs Placebo -0.02 SDS score (Standard Deviation 0.54) (met)
Result source: NCT02918279
Semaglutide (Wegovy)
Marketed by Novo Nordisk
NCT03548935 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 1,961 participants. At week 68, mean body-weight change was -15.6% with semaglutide versus -2.8% with placebo, and the primary comparison was statistically significant (p<0.0001), supporting strong evidence for this clinical weight-loss endpoint.
Next expected readout: December 2026 · NCT05173714 (registry estimate)
Reported efficacy
Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801 (met)
Result source: NCT03574597
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Liraglutide (Saxenda) | Semaglutide (Wegovy) |
|---|---|---|
| Body weight, % change | -8.0% vs -2.6%−5.4 vs placeboNCT0127221920 other results
| -19.5% vs -3.8%−15.7 vs placeboNCT0564670628 other results
|
| Weight loss of 5% or more | 63.2% vs 27.1%+36.1 vs placeboNCT012722194 other results
| 87% vs 29.2%+57.8 vs placeboNCT050647351 other result
|
| Weight loss of 10% or more | 33.1% vs 10.6%+22.5 vs placeboNCT012722193 other results
| 70.4% vs 9.2%+61.2 vs placeboNCT050647359 other results
|
| Waist circumference, change (cm) | -8.2 vs -3.9−4.2 vs placeboNCT0127221924 other results
| -7.5 vs -1−6.5 vs placeboNCT0357459735 other results
|
Body weight, % change
- Liraglutide (Saxenda)
- -8.0% vs -2.6%−5.4 vs placeboNCT01272219
20 other results
- -6.1% vs -0.1% NCT00781937
- -5.9% vs -2% NCT01272232
- -4.6% vs -2% NCT01272232
- -7.7% vs -6.5% NCT03374956
- -6.1% vs -1.9% NCT01272219
- 0.7% vs 0.3% NCT01272219
- 2.9% vs 0.3% NCT01272219
- -8.4% vs -3.1% NCT01272219
- -6.8% vs -3.1% NCT01272219
- -4.7% vs -2.7% NCT01272232
- -3.6% vs -2.7% NCT01272232
- -5.7% vs -1.4% NCT03480022
- -0.4% vs 3.3% NCT02527200
- 6.3% vs 3.3% NCT02527200
- 2.6% vs 3.3% NCT02527200
- -1.7% vs -1.2% NCT02527200
- -1.1% vs -1.2% NCT02527200
- -1.4% vs -1.2% NCT02527200
- -3.3% vs 0.2% NCT03158805
- -6.6% vs -1.2% NCT03038620
- Semaglutide (Wegovy)
- -19.5% vs -3.8%−15.7 vs placeboNCT05646706
28 other results
- -14.2% vs -2.5% NCT05064735
- -13.4% vs -1.9% NCT03811574
- -14.4% vs -2.7% NCT05040971
- -13.9% vs -2.5% NCT04788511
- -12.2% vs -2.2% NCT06041217
- -12.5% vs -3.6% NCT04251156
- -9.9% vs -1.9% NCT03811574
- -16.4% vs -2.6% NCT04998136
- -16.4% vs -2.7% NCT04998136
- -16.4% vs -6.4% NCT04074161
- -9.4% vs -0.9% NCT03574597
- -17.7% vs -5.4% NCT03548987
- -7.8% vs -6% NCT03611582
- -14.8% vs 2.3% NCT04102189
- -16.4% vs -1.6% NCT04074161
- -15.8% vs -3.3% NCT03693430
- -9.9% vs -7.2% NCT03552757
- -19.5% vs -16.4% NCT05646706
- -5.5% vs -3.1% NCT04969939
- -13.8% vs -2.3% NCT02453711
- -16.3% vs -2.3% NCT02453711
- -11.2% vs -2.3% NCT02453711
- -11.4% vs -2.3% NCT02453711
- -11.6% vs -2.3% NCT02453711
- -8.6% vs -2.3% NCT02453711
- -6.0% vs -2.3% NCT02453711
- -4.5% vs -0.2% NCT04779697
- -13.6% vs -7.4% NCT05579249
Weight loss of 5% or more
- Liraglutide (Saxenda)
- 63.2% vs 27.1%+36.1 vs placeboNCT01272219
4 other results
- 50.5% vs 21.9% NCT00781937
- 49.9% vs 13.8% NCT01272232
- 35.6% vs 13.8% NCT01272232
- 76% vs 17% NCT03048578
- Semaglutide (Wegovy)
- 87% vs 29.2%+57.8 vs placeboNCT05064735
1 other result
- 72.5% vs 17.7% NCT04102189
Weight loss of 10% or more
- Liraglutide (Saxenda)
- 33.1% vs 10.6%+22.5 vs placeboNCT01272219
3 other results
- 23.4% vs 4.3% NCT01272232
- 14.4% vs 4.3% NCT01272232
- 26.1% vs 6.3% NCT00781937
- Semaglutide (Wegovy)
- 70.4% vs 9.2%+61.2 vs placeboNCT05064735
9 other results
- 61.8% vs 8.1% NCT04102189
- 65.9% vs 9.5% NCT04788511
- 64.6% vs 10.1% NCT02453711
- 71.9% vs 10.1% NCT02453711
- 57.8% vs 10.1% NCT02453711
- 58.5% vs 10.1% NCT02453711
- 56.0% vs 10.1% NCT02453711
- 36.6% vs 10.1% NCT02453711
- 18.9% vs 10.1% NCT02453711
Waist circumference, change (cm)
- Liraglutide (Saxenda)
- -8.2 vs -3.9−4.2 vs placeboNCT01272219
24 other results
- -6.9 vs -3.4 NCT01272219
- -5.7 vs -3.2 NCT01272232
- -4.4 vs -0.9 NCT00781937
- -6.1 vs -2.7 NCT01272232
- -4.4 vs -3.2 NCT01272232
- -4.8 vs -2.7 NCT01272232
- 100.9 vs 109.9 NCT03480022
- -3.0 vs -2.1 NCT02527200
- 0.5 vs -2.1 NCT02527200
- -1.5 vs -2.1 NCT02527200
- -2.5 vs -1.9 NCT02527200
- -0.7 vs -1.9 NCT02527200
- -1.7 vs -1.9 NCT02527200
- -7.4 vs -4.6 NCT03038620
- -9.8 vs -9.5 NCT00422058
- -7.9 vs -6 NCT00422058
- -9 vs -9.5 NCT00422058
- -5.9 vs -6 NCT00422058
- -10 vs -9.5 NCT00422058
- -10.4 vs -9.5 NCT00422058
- -4.2 vs -6 NCT00422058
- -7.2 vs -6 NCT00422058
- -8.6 vs -9.5 NCT00422058
- -5.8 vs -6 NCT00422058
- Semaglutide (Wegovy)
- -7.5 vs -1−6.5 vs placeboNCT03574597
35 other results
- -14.1 vs -4.4 NCT03548935
- -6.9 vs 3.2 NCT03548987
- -15.2 vs -4.3 NCT03693430
- -9.7 vs -4.3 NCT03552757
- -15.2 vs -6.1 NCT03611582
- -18 vs -5.6 NCT05646706
- -13.3 vs -5.9 NCT05064735
- -12.7 vs -0.5 NCT04102189
- -13.6 vs -2 NCT04074161
- -11.2 vs -1.8 NCT03811574
- -10.2 vs -1.9 NCT03811574
- -11.6 vs -2.8 NCT05040971
- -12 vs -2.8 NCT04788511
- -14.3 vs -4.5 NCT03693430
- -9.1 vs -2.4 NCT06041217
- -11.1 vs -3.8 NCT04251156
- -7.8 vs -1.8 NCT03811574
- -7.6 vs -1.9 NCT03811574
- -12 vs -3 NCT04998136
- -4.8 vs -2.7 NCT04969939
- -12.3 vs -3.5 NCT02453711
- -14.9 vs -3.5 NCT02453711
- -10.9 vs -3.5 NCT02453711
- -11.1 vs -3.5 NCT02453711
- -11.0 vs -3.5 NCT02453711
- -8.8 vs -3.5 NCT02453711
- -6.1 vs -3.5 NCT02453711
- -18.2 vs -14.7 NCT05616013
- -21.3 vs -14.7 NCT05616013
- -15.8 vs -13.6 NCT05616013
- -19.0 vs -13.6 NCT05616013
- -15.6 vs -14.7 NCT05616013
- -18.1 vs -14.7 NCT05616013
- -14.6 vs -13.6 NCT05616013
- -16.6 vs -13.6 NCT05616013
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
25 other shared endpoints and safety
Coverage. Liraglutide (Saxenda): 29 of 29 rows · Semaglutide (Wegovy): 29 of 29 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Liraglutide (Saxenda) Rows use multiple source trials | Semaglutide (Wegovy) Rows use multiple source trials |
|---|---|---|
| BMI absolute change · kg | 0.8 vs -0.1 placebo kg @ 52wka,b NCT02527200 · Phase 3 · registry result, not featured evidence show 2 more doses-0.7 vs -0.1 placebo kg @ 52wk NCT02527200 · Phase 3 · registry result, not featured evidence · combination -0.6 vs -0.1 placebo kg @ 52wk NCT02527200 · Phase 3 · registry result, not featured evidence | -6.1 vs -1.3 placebo kg @ 52wk2.4 mgb NCT03693430 · Phase 3 · registry result, not featured evidence 7 other source trials-2.37 vs -0.88 placebo kg @ 52wk0.05 mg NCT02453711 · Phase 2 · registry result, not featured evidence -3.36 vs -0.88 placebo kg @ 52wk0.1 mg NCT02453711 · Phase 2 · registry result, not featured evidence -4.38 vs -0.88 placebo kg @ 52wk0.2 mg NCT02453711 · Phase 2 · registry result, not featured evidence -4.4 vs -0.88 placebo kg @ 52wk0.3 mg NCT02453711 · Phase 2 · registry result, not featured evidence -4.48 vs -0.88 placebo kg @ 52wk0.3 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence -5.4 vs -0.88 placebo kg @ 52wk0.4 mg NCT02453711 · Phase 2 · registry result, not featured evidence -6.21 vs -0.88 placebo kg @ 52wk0.4 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence |
| BMI Loss 5% responder rate · % of participants | 29.4% (n=17) vs 18.2% (n=11) placebo @ 52wka,c,d NCT02527200 · Phase 3 · registry result, not featured evidence show 2 more doses32.3% (n=31) vs 18.2% (n=11) placebo @ 52wk NCT02527200 · Phase 3 · registry result, not featured evidence · combination 35.7% (n=14) vs 18.2% (n=11) placebo @ 52wk NCT02527200 · Phase 3 · registry result, not featured evidence | 75.6% (n=131) vs 22.6% (n=62) placebo @ 68wk2.4 mgc,d Yes NCT04102189 · Phase 3 · registry result, not featured evidence |
| BMI SDS absolute change · score | -0.25 vs -0.02 placebo score @ 56wk3.0 mge,f,g NCT02918279 · Phase 3 | -1.1 vs -0.1 placebo score @ 68wk2.4 mge,f,g NCT04102189 · Phase 3 · registry result, not featured evidence |
| Body Fat percent change · % of baseline | 46% (n=44) vs 47.9% (n=23) placebo @ 32wk3 mgh,i,f,j NCT03480022 · Phase 3 · registry result, not featured evidence | -37.26% (n=41) vs -18.97% (n=38) semaglutide @ 72wk30 mg/kg + 1.0 mga,h,i,f,j NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 show 7 more doses-8.71% (n=42) vs -3.06% (n=40) semaglutide @ 72wk30 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 -45.42% (n=34) vs -18.97% (n=38) semaglutide @ 72wk30 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 -11.33% (n=39) vs -3.06% (n=40) semaglutide @ 72wk30 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 -33.58% (n=32) vs -18.97% (n=38) semaglutide @ 72wk10 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 -7.43% (n=34) vs -3.06% (n=40) semaglutide @ 72wk10 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 -39.46% (n=38) vs -18.97% (n=38) semaglutide @ 72wk10 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 -8.29% (n=39) vs -3.06% (n=40) semaglutide @ 72wk10 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 |
| CRP Change absolute change · mg | -2.18 vs -0.64 placebo mg @ 40wk3.0 mgk,e,f,l NCT03038620 · Phase 4 · registry result, not featured evidence | 0.54 vs 0.82 placebo mg @ 52wk0.4 mga,k,e,f,l NCT02453711 · Phase 2 · registry result, not featured evidence show 6 more doses0.44 vs 0.82 placebo mg @ 52wk0.4 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence 0.66 vs 0.82 placebo mg @ 52wk0.3 mg NCT02453711 · Phase 2 · registry result, not featured evidence 0.58 vs 0.82 placebo mg @ 52wk0.3 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence 0.57 vs 0.82 placebo mg @ 52wk0.2 mg NCT02453711 · Phase 2 · registry result, not featured evidence 0.65 vs 0.82 placebo mg @ 52wk0.1 mg NCT02453711 · Phase 2 · registry result, not featured evidence 0.71 vs 0.82 placebo mg @ 52wk0.05 mg NCT02453711 · Phase 2 · registry result, not featured evidence |
| DBP absolute change · mmHg | -1 vs -1 placebo mmHg @ 56wk3.0 mge,f,m NCT02963935 · Phase 3 · registry result, not featured evidence | -4 vs -1 placebo mmHg @ 104wk2.4 mge,f,m NCT03693430 · Phase 3 · registry result, not featured evidence |
| Fasting Insulin absolute change · pmol/L | -19.6 vs -15.3 Orlistat pmol/L @ 104wk3.0 mga,e,f,n NCT00422058 · Phase 2 · registry result, not featured evidence show 4 more doses18.6 vs -15.3 Orlistat pmol/L @ 104wk1.8 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence -2.1 vs -15.3 Orlistat pmol/L @ 104wk2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 0.7 vs -15.3 Orlistat pmol/L @ 104wkplacebo / 2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence -13.5 vs -15.3 Orlistat pmol/L @ 104wk1.2 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence | -14.1 vs -8.1 placebo pmol/L @ 48wk1.0 mg + 2.4 mge,f,n NCT04969939 · Phase 2 · registry result, not featured evidence · combination |
| Fasting Insulin absolute change · ratio | 2.03 vs 0.79 placebo ratio @ 52wka,c,d NCT02527200 · Phase 3 · registry result, not featured evidence show 2 more doses1.78 vs 0.79 placebo ratio @ 52wk NCT02527200 · Phase 3 · registry result, not featured evidence · combination 1.45 vs 0.79 placebo ratio @ 52wk NCT02527200 · Phase 3 · registry result, not featured evidence | 0.81 vs 1.03 placebo ratio @ 68wk2.4 mgc,d NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 2 other source trials0.64 vs 0.99 placebo ratio @ 68wk2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence 0.64 vs 0.99 placebo ratio @ 68wk2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence |
| Fasting Plasma Glucose absolute change · mmol/L | -0.23 vs 0.02 Orlistat mmol/L @ 104wk3.0 mga,o,e,f NCT00422058 · Phase 2 · registry result, not featured evidence show 4 more doses-0.09 vs 0.02 Orlistat mmol/L @ 104wk1.8 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence -0.2 vs 0.02 Orlistat mmol/L @ 104wk2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence -0.22 vs 0.02 Orlistat mmol/L @ 104wkplacebo / 2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence -0.09 vs 0.02 Orlistat mmol/L @ 104wk1.2 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence | -0.5 vs 0.1 placebo mmol/L @ 104wk2.4 mga,o,e,f NCT03693430 · Phase 3 · registry result, not featured evidence show 1 more dose-0.46 vs 0.1 placebo mmol/L @ 104wk*2.4 mg NCT03693430 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -8.3 mg/dL as posted |
| Free Fatty Acids absolute change · ratio | 1.15 vs 1.45 placebo ratio @ 52wka,c,d NCT02527200 · Phase 3 · registry result, not featured evidence show 2 more doses1.01 vs 1.45 placebo ratio @ 52wk NCT02527200 · Phase 3 · registry result, not featured evidence · combination 0.85 vs 1.45 placebo ratio @ 52wk NCT02527200 · Phase 3 · registry result, not featured evidence | 0.86 vs 1.08 placebo ratio @ 68wk2.4 mgc,d NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 2 other source trials1.04 vs 1.28 placebo ratio @ 68wk1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence 0.96 vs 1.28 placebo ratio @ 68wk2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence |
| HbA1c absolute change · percentage points | -0.35% (n=47) vs -0.18% (n=45) Orlistat @ 104wk3.0 mga,o,e,f NCT00422058 · Phase 2 · registry result, not featured evidence show 4 more doses-0.3% (n=36) vs -0.18% (n=45) Orlistat @ 104wk1.8 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence -0.25% (n=45) vs -0.18% (n=45) Orlistat @ 104wk2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence -0.32% (n=46) vs -0.18% (n=45) Orlistat @ 104wkplacebo / 2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence -0.25% (n=45) vs -0.18% (n=45) Orlistat @ 104wk1.2 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence | -0.31% (n=7439) vs 0.01% (n=7351) placebo @ 104wko,e,f NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3 1 other source trial-0.5% (n=141) vs -0.1% (n=122) placebo @ 104wk2.4 mg NCT03693430 · Phase 3 · registry result, not featured evidence |
| HDL-C absolute change · ratio | 0.99 vs 1.02 placebo ratio @ 52wka,c,p NCT02527200 · Phase 3 · registry result, not featured evidence show 2 more doses1.02 vs 1.02 placebo ratio @ 52wk NCT02527200 · Phase 3 · registry result, not featured evidence · combination 1.06 vs 1.02 placebo ratio @ 52wk NCT02527200 · Phase 3 · registry result, not featured evidence | 1.05 vs 1.01 placebo ratio @ 104wkc,p NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3 |
| IWQOL-Lite-CT Physical Function responder rate · % of participants | 25.3% (n=198) vs 24.2% (n=198) placebo @ 56wk3.0 mgq,b,f,g NCT02963922 · Phase 3 · registry result, not featured evidence 1 other source trial37.3% (n=142) vs 34.3% (n=140) placebo @ 56wk3.0 mg NCT02963935 · Phase 3 · registry result, not featured evidence | 25.5% (n=192) vs 11% (n=100) placebo @ 68wk*2.4 mga,q,b,f,g NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 49 Participants as posted show 1 more dose19.4% (n=98) vs 11% (n=100) placebo @ 68wk*1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 19 Participants as posted |
| LDL-C absolute change · ratio | 1.02 vs 1.12 placebo ratio @ 52wka,c,p NCT02527200 · Phase 3 · registry result, not featured evidence show 2 more doses1.01 vs 1.12 placebo ratio @ 52wk NCT02527200 · Phase 3 · registry result, not featured evidence · combination 0.99 vs 1.12 placebo ratio @ 52wk NCT02527200 · Phase 3 · registry result, not featured evidence | 0.95 vs 0.97 placebo ratio @ 104wkc,p NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3 |
| Lean Mass percent change · % of baseline | -2.47% (n=73) vs -0.9% (n=55) placebo @ 40wk*3.0 mgk,e,f,r NCT03038620 · Phase 4 · registry result, not featured evidence · converted to % from 2.47 percent change as posted | -1.38% (n=41) vs -5.09% (n=38) semaglutide @ 72wk30 mg/kg + 1.0 mga,k,e,f,r NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 show 7 more doses6.79% (n=42) vs 2.8% (n=40) semaglutide @ 72wk30 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 -3% (n=34) vs -5.09% (n=38) semaglutide @ 72wk30 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 10.64% (n=39) vs 2.8% (n=40) semaglutide @ 72wk30 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 -1.96% (n=32) vs -5.09% (n=38) semaglutide @ 72wk10 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 6.52% (n=34) vs 2.8% (n=40) semaglutide @ 72wk10 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 -2.89% (n=38) vs -5.09% (n=38) semaglutide @ 72wk10 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 6.89% (n=39) vs 2.8% (n=40) semaglutide @ 72wk10 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 |
| SBP absolute change · mmHg | -2 vs -1 placebo mmHg @ 56wk3.0 mge,f,m NCT02963935 · Phase 3 · registry result, not featured evidence | -3.8 vs -0.6 placebo mmHg @ 104wke,f,m NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3 1 other source trial-6 vs -1 placebo mmHg @ 104wk2.4 mg NCT03693430 · Phase 3 · registry result, not featured evidence |
| SF-36 Physical Functioning responder rate · % of participants | 28.8% (n=198) vs 26.3% (n=198) placebo @ 56wk3.0 mgq,b,f,g NCT02963922 · Phase 3 · registry result, not featured evidence 1 other source trial38.7% (n=142) vs 37.9% (n=140) placebo @ 56wk3.0 mg NCT02963935 · Phase 3 · registry result, not featured evidence | 22.4% (n=192) vs 13% (n=100) placebo @ 68wk*2.4 mga,q,b,f,g NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 43 Participants as posted show 1 more dose19.4% (n=98) vs 13% (n=100) placebo @ 68wk*1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 19 Participants as posted |
| Total Cholesterol absolute change · ratio | 1 vs 1.06 placebo ratio @ 52wka,c,p NCT02527200 · Phase 3 · registry result, not featured evidence show 2 more doses1.01 vs 1.06 placebo ratio @ 52wk NCT02527200 · Phase 3 · registry result, not featured evidence · combination 1.01 vs 1.06 placebo ratio @ 52wk NCT02527200 · Phase 3 · registry result, not featured evidence | 0.95 vs 0.98 placebo ratio @ 104wkc,p NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3 |
| Triglycerides absolute change · ratio | 1.07 vs 0.94 placebo ratio @ 52wka,c,p NCT02527200 · Phase 3 · registry result, not featured evidence show 2 more doses1.06 vs 0.94 placebo ratio @ 52wk NCT02527200 · Phase 3 · registry result, not featured evidence · combination 1.04 vs 0.94 placebo ratio @ 52wk NCT02527200 · Phase 3 · registry result, not featured evidence | 0.82 vs 0.97 placebo ratio @ 104wkc,p NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3 |
| VLDL-C absolute change · ratio | 1.06 vs 0.95 placebo ratio @ 52wka,c,s NCT02527200 · Phase 3 · registry result, not featured evidence show 2 more doses1.04 vs 0.95 placebo ratio @ 52wk NCT02527200 · Phase 3 · registry result, not featured evidence · combination 1.03 vs 0.95 placebo ratio @ 52wk NCT02527200 · Phase 3 · registry result, not featured evidence | 0.76 vs 1 placebo ratio @ 72wk7.2 mga,c,s NCT05646706 · Phase 3 · registry result, not featured evidence show 1 more dose0.76 vs 1 placebo ratio @ 72wk7.2 mg NCT05646706 · Phase 3 · registry result, not featured evidence |
| Waist-Hip ratio to baseline · ratio | -0.01 vs -0.04 placebo ratio @ 52wka,h,c NCT02527200 · Phase 3 · registry result, not featured evidence show 2 more doses-0.02 vs -0.04 placebo ratio @ 52wk NCT02527200 · Phase 3 · registry result, not featured evidence · combination -0.02 vs -0.04 placebo ratio @ 52wk NCT02527200 · Phase 3 · registry result, not featured evidence | -0.02 vs -0.01 placebo ratio @ 52wk0.4 mga,h,c NCT02453711 · Phase 2 · registry result, not featured evidence show 6 more doses-0.03 vs -0.01 placebo ratio @ 52wk0.4 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence -0.03 vs -0.01 placebo ratio @ 52wk0.3 mg NCT02453711 · Phase 2 · registry result, not featured evidence -0.02 vs -0.01 placebo ratio @ 52wk0.3 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence -0.02 vs -0.01 placebo ratio @ 52wk0.2 mg NCT02453711 · Phase 2 · registry result, not featured evidence -0.02 vs -0.01 placebo ratio @ 52wk0.1 mg NCT02453711 · Phase 2 · registry result, not featured evidence -0.01 vs -0.01 placebo ratio @ 52wk0.05 mg NCT02453711 · Phase 2 · registry result, not featured evidence |
| Weight absolute change · kg | -8.2 vs -3.8 Orlistat kg @ 104wk3.0 mga,o,e,f NCT00422058 · Phase 2 · registry result, not featured evidence show 4 more doses-5.6 vs -3.8 Orlistat kg @ 104wk1.8 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence -6.4 vs -3.8 Orlistat kg @ 104wk2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence -5.4 vs -3.8 Orlistat kg @ 104wkplacebo / 2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence -4.9 vs -3.8 Orlistat kg @ 104wk1.2 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence | -16.9 vs -2.1 placebo kg @ 104wk2.4 mgo,e,f NCT03693430 · Phase 3 · registry result, not featured evidence |
| Weight percent change · % of baseline In-trial observation period | -6% (n=198) vs -1.5% (n=198) placebo @ 56wk3.0 mgb,f,m In-trial observation period NCT02963922 · Phase 3 · registry result, not featured evidence 1 other source trial-7.4% (n=142) vs -4% (n=140) placebo @ 56wk3.0 mg In-trial observation period NCT02963935 · Phase 3 · registry result, not featured evidence | -15.9% (n=144) vs -1.9% (n=128) placebo @ 104wk2.4 mgb,f,m In-trial observation period NCT03693430 · Phase 3 · registry result, not featured evidence |
| Weight Loss 10% event count · % of participants | 29.5% (n=44) vs 8.7% (n=23) placebo @ 32wk*3 mgq,i,f,t NCT03480022 · Phase 3 · registry result, not featured evidence · converted to % from 13 Participants as posted | 61.8% (n=144) vs 13.3% (n=128) placebo @ 104wk*2.4 mgq,i,f,t Yes NCT03693430 · Phase 3 · registry result, not featured evidence · converted to % from 89 Participants as posted |
| Weight Loss 5% event count · % of participants | 56.8% (n=44) vs 21.7% (n=23) placebo @ 32wk*3 mgq,i,f,j NCT03480022 · Phase 3 · registry result, not featured evidence · converted to % from 25 Participants as posted | 90.7% (n=950) vs 36.8% (n=171) placebo @ 72wk*7.2 mgq,i,f,j Yes NCT05646706 · Phase 3 · registry result, not featured evidence · converted to % from 862 Participants as posted |
| Dropout rate | 25%3.0 mgu NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3 show 38 more results27.4%3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 29.2%3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 —3.0 mg NCT01272219 · Phase 3 · monotherapy · Obesity · phase 3 —3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 23.4%3.0 mg NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3 22.3%1.8 mg NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3 25.6%3.0 mg NCT01557166 · Phase 3 · monotherapy · Obesity · phase 3 10.4%3.0 mg NCT02918279 · Phase 3 22.7%3 mg NCT03036800 · Phase 4 · registry result, not featured evidence · combination 34.8% NCT03048578 · Phase 4 · registry result, not featured evidence 20.7%3.0 mg NCT03038620 · Phase 4 · registry result, not featured evidence 10% NCT02911818 · Phase 4 · registry result, not featured evidence — NCT01562678 · Phase 4 · registry result, not featured evidence 0% NCT03115424 · Phase 3 · registry result, not featured evidence 0% NCT03374956 · Phase 3 · registry result, not featured evidence · Obesity · phase 3 20%3 mg NCT03480022 · Phase 3 · registry result, not featured evidence 15%Part A: Liraglutide NCT02527200 · Phase 3 · registry result, not featured evidence 11.8%Part B: Liraglutide NCT02527200 · Phase 3 · registry result, not featured evidence 16.2%3.0 mg NCT02963922 · Phase 3 · registry result, not featured evidence —3.0 mg NCT02963935 · Phase 3 · registry result, not featured evidence 19.7%3.0 mg NCT02963935 · Phase 3 · registry result, not featured evidence 31.4% NCT01784965 · Phase 3 · registry result, not featured evidence 8.8% NCT04883346 · Phase 2 · registry result, not featured evidence 55.2% NCT03158805 · Phase 2 · registry result, not featured evidence 11.9% NCT03523273 · Phase 2 · registry result, not featured evidence 10.5% NCT02647944 · Phase 2 · registry result, not featured evidence 11.8%3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 17.8%1.8 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 21.5%2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 19.4%placebo / 2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 10.5%1.2 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 16.7%420 mg NCT03757130 · Phase 1 · registry result, not featured evidence 16.7%AMG 598 420 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination 0%210 mg NCT03757130 · Phase 1 · registry result, not featured evidence 0%AMG 598 210 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination 0%70 mg NCT03757130 · Phase 1 · registry result, not featured evidence 12.5%AMG 598 70 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination 12.5% NCT03041792 · Phase 1 · registry result, not featured evidence | —2.4 mg weeklyu NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 show 40 more results5.1%2.4 mg weekly NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 11%2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 —2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 3.2%2.4 mg NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 2.9% NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3 16.7%2.4 mg NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 15.3%Behavioral Treatment + Medication NCT05548647 · Phase 4 · registry result, not featured evidence · combination —Continued Medication (Semaglutide) NCT05548647 · Phase 4 · registry result, not featured evidence 14.4%2.4 mg NCT05579249 · Phase 4 · registry result, not featured evidence —2.4 mg NCT06041217 · Phase 3 · registry result, not featured evidence 0%2.4 mg NCT06041217 · Phase 3 · registry result, not featured evidence 4.6%7.2 mg NCT05646706 · Phase 3 · registry result, not featured evidence 0% NCT04998136 · Phase 3 · registry result, not featured evidence 9.2%2.4 mg NCT05064735 · Phase 3 · registry result, not featured evidence 7.2%2.4 mg NCT05040971 · Phase 3 · registry result, not featured evidence 2.7%2.4 mg NCT04788511 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04251156 · Phase 3 · registry result, not featured evidence 2%2.4 mg NCT04251156 · Phase 3 · registry result, not featured evidence 1.5%2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence 4.8%2.4 mg NCT04074161 · Phase 3 · registry result, not featured evidence 2.6%2.4 mg NCT03693430 · Phase 3 · registry result, not featured evidence 2%2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence 2%1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence 33.9%30 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 38.6%30 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 50%10 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 37.5%10 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 12.5% NCT05302596 · Phase 2 · registry result, not featured evidence 0%2.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination —2.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination 0%1.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination —1.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination 2%0.4 mg NCT02453711 · Phase 2 · registry result, not featured evidence 2.9%0.4 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence 6.8%0.3 mg NCT02453711 · Phase 2 · registry result, not featured evidence 5.9%0.3 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence 8.7%0.2 mg NCT02453711 · Phase 2 · registry result, not featured evidence 6.9%0.1 mg NCT02453711 · Phase 2 · registry result, not featured evidence 10.7%0.05 mg NCT02453711 · Phase 2 · registry result, not featured evidence 10.4% NCT04779697 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 8.5%3.0 mgu NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3 show 38 more results9.9%3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 9%3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 —3.0 mg NCT01272219 · Phase 3 · monotherapy · Obesity · phase 3 —3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 9.2%3.0 mg NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3 8.5%1.8 mg NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3 11.1%3.0 mg NCT01557166 · Phase 3 · monotherapy · Obesity · phase 3 —3.0 mg NCT02918279 · Phase 3 —3 mg NCT03036800 · Phase 4 · registry result, not featured evidence · combination 1.1% NCT03048578 · Phase 4 · registry result, not featured evidence —3.0 mg NCT03038620 · Phase 4 · registry result, not featured evidence — NCT02911818 · Phase 4 · registry result, not featured evidence — NCT01562678 · Phase 4 · registry result, not featured evidence — NCT03115424 · Phase 3 · registry result, not featured evidence — NCT03374956 · Phase 3 · registry result, not featured evidence · Obesity · phase 3 10.9%3 mg NCT03480022 · Phase 3 · registry result, not featured evidence —Part A: Liraglutide NCT02527200 · Phase 3 · registry result, not featured evidence —Part B: Liraglutide NCT02527200 · Phase 3 · registry result, not featured evidence 7.6%3.0 mg NCT02963922 · Phase 3 · registry result, not featured evidence —3.0 mg NCT02963935 · Phase 3 · registry result, not featured evidence 8.5%3.0 mg NCT02963935 · Phase 3 · registry result, not featured evidence 22.9% NCT01784965 · Phase 3 · registry result, not featured evidence — NCT04883346 · Phase 2 · registry result, not featured evidence — NCT03158805 · Phase 2 · registry result, not featured evidence — NCT03523273 · Phase 2 · registry result, not featured evidence 10.5% NCT02647944 · Phase 2 · registry result, not featured evidence 5.4%3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 5.6%1.8 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 9.7%2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 3.1%placebo / 2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 4.2%1.2 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence —420 mg NCT03757130 · Phase 1 · registry result, not featured evidence —AMG 598 420 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination —210 mg NCT03757130 · Phase 1 · registry result, not featured evidence —AMG 598 210 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination —70 mg NCT03757130 · Phase 1 · registry result, not featured evidence —AMG 598 70 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination 12.5% NCT03041792 · Phase 1 · registry result, not featured evidence | —2.4 mg weeklyu NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 show 40 more results—2.4 mg weekly NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 5.3%2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 —2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 —2.4 mg NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 — NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3 6.4%2.4 mg NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 —Behavioral Treatment + Medication NCT05548647 · Phase 4 · registry result, not featured evidence · combination —Continued Medication (Semaglutide) NCT05548647 · Phase 4 · registry result, not featured evidence —2.4 mg NCT05579249 · Phase 4 · registry result, not featured evidence —2.4 mg NCT06041217 · Phase 3 · registry result, not featured evidence —2.4 mg NCT06041217 · Phase 3 · registry result, not featured evidence —7.2 mg NCT05646706 · Phase 3 · registry result, not featured evidence — NCT04998136 · Phase 3 · registry result, not featured evidence —2.4 mg NCT05064735 · Phase 3 · registry result, not featured evidence —2.4 mg NCT05040971 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04788511 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04251156 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04251156 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04074161 · Phase 3 · registry result, not featured evidence —2.4 mg NCT03693430 · Phase 3 · registry result, not featured evidence —2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence —1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence 10.7%30 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 1.8%30 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 14.3%10 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 5.4%10 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 — NCT05302596 · Phase 2 · registry result, not featured evidence —2.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination —2.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination —1.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination —1.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination —0.4 mg NCT02453711 · Phase 2 · registry result, not featured evidence —0.4 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence —0.3 mg NCT02453711 · Phase 2 · registry result, not featured evidence —0.3 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence —0.2 mg NCT02453711 · Phase 2 · registry result, not featured evidence —0.1 mg NCT02453711 · Phase 2 · registry result, not featured evidence —0.05 mg NCT02453711 · Phase 2 · registry result, not featured evidence — NCT04779697 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 4.2%3.0 mgu NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3 show 38 more results15.1%3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 6.2%3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 —3.0 mg NCT01272219 · Phase 3 · monotherapy · Obesity · phase 3 —3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 8.8%3.0 mg NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3 8.6%1.8 mg NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3 3.4%3.0 mg NCT01557166 · Phase 3 · monotherapy · Obesity · phase 3 2.4%3.0 mg NCT02918279 · Phase 3 16.5%3 mg NCT03036800 · Phase 4 · registry result, not featured evidence · combination 4.5% NCT03048578 · Phase 4 · registry result, not featured evidence 0%3.0 mg NCT03038620 · Phase 4 · registry result, not featured evidence 0% NCT02911818 · Phase 4 · registry result, not featured evidence 0% NCT01562678 · Phase 4 · registry result, not featured evidence 8.3% NCT03115424 · Phase 3 · registry result, not featured evidence 0% NCT03374956 · Phase 3 · registry result, not featured evidence · Obesity · phase 3 0%3 mg NCT03480022 · Phase 3 · registry result, not featured evidence 5%Part A: Liraglutide NCT02527200 · Phase 3 · registry result, not featured evidence 11.8%Part B: Liraglutide NCT02527200 · Phase 3 · registry result, not featured evidence 8.2%3.0 mg NCT02963922 · Phase 3 · registry result, not featured evidence 4.2%3.0 mg NCT02963935 · Phase 3 · registry result, not featured evidence —3.0 mg NCT02963935 · Phase 3 · registry result, not featured evidence 22.9% NCT01784965 · Phase 3 · registry result, not featured evidence 0% NCT04883346 · Phase 2 · registry result, not featured evidence 0% NCT03158805 · Phase 2 · registry result, not featured evidence 1.5% NCT03523273 · Phase 2 · registry result, not featured evidence 0% NCT02647944 · Phase 2 · registry result, not featured evidence 10.8%3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 11.1%1.8 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 7.5%2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 6.1%placebo / 2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 9.5%1.2 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 0%420 mg NCT03757130 · Phase 1 · registry result, not featured evidence 0%AMG 598 420 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination 0%210 mg NCT03757130 · Phase 1 · registry result, not featured evidence 0%AMG 598 210 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination 0%70 mg NCT03757130 · Phase 1 · registry result, not featured evidence 0%AMG 598 70 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination 0% NCT03041792 · Phase 1 · registry result, not featured evidence | 9.8%2.4 mg weeklyu NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 show 40 more results—2.4 mg weekly NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 —2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 7.7%2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 9.9%2.4 mg NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 33.4% NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3 9.1%2.4 mg NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 4.2%Behavioral Treatment + Medication NCT05548647 · Phase 4 · registry result, not featured evidence · combination 0%Continued Medication (Semaglutide) NCT05548647 · Phase 4 · registry result, not featured evidence 1.2%2.4 mg NCT05579249 · Phase 4 · registry result, not featured evidence 8.1%2.4 mg NCT06041217 · Phase 3 · registry result, not featured evidence —2.4 mg NCT06041217 · Phase 3 · registry result, not featured evidence 7.3%7.2 mg NCT05646706 · Phase 3 · registry result, not featured evidence 12.9% NCT04998136 · Phase 3 · registry result, not featured evidence 10%2.4 mg NCT05064735 · Phase 3 · registry result, not featured evidence 8.7%2.4 mg NCT05040971 · Phase 3 · registry result, not featured evidence 13.3%2.4 mg NCT04788511 · Phase 3 · registry result, not featured evidence 5.6%2.4 mg NCT04251156 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04251156 · Phase 3 · registry result, not featured evidence 11.3%2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence 7.9%2.4 mg NCT04074161 · Phase 3 · registry result, not featured evidence 7.9%2.4 mg NCT03693430 · Phase 3 · registry result, not featured evidence 5%2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence 7%1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence 10.7%30 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 12.7%30 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 12.5%10 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 14.5%10 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 0% NCT05302596 · Phase 2 · registry result, not featured evidence 12.5%2.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination 0%2.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination 0%1.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination 4.3%1.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination 12.7%0.4 mg NCT02453711 · Phase 2 · registry result, not featured evidence 6.8%0.4 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence 5.8%0.3 mg NCT02453711 · Phase 2 · registry result, not featured evidence 5.9%0.3 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence 4.9%0.2 mg NCT02453711 · Phase 2 · registry result, not featured evidence 7.8%0.1 mg NCT02453711 · Phase 2 · registry result, not featured evidence 12.6%0.05 mg NCT02453711 · Phase 2 · registry result, not featured evidence 2.1% NCT04779697 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 3.0 mgu nausea 47.6% (placebo 17.1%) constipation 26.9% (placebo 12.4%) diarrhoea 17.9% (placebo 12.4%) NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3 show 35 more results3.0 mg nausea 40.8% (placebo 17%) nasopharyngitis 26.5% (placebo 27.8%) diarrhoea 25.5% (placebo 14.2%) NCT01272219 · Phase 3 · Obesity · phase 3 3.0 mg nausea 43.7% (placebo 17%) constipation 21.2% (placebo 11.3%) diarrhoea 21% (placebo 14.2%) NCT01272219 · Phase 3 · Obesity · phase 3 3.0 mg hypoglycaemia 44.3% (placebo 27.8%) nausea 32.7% (placebo 13.7%) diarrhoea 25.6% (placebo 12.7%) NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3 1.8 mg hypoglycaemia 40% (placebo 27.8%) nausea 31.4% (placebo 13.7%) diarrhoea 17.6% (placebo 12.7%) NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3 3.0 mg nausea 26.7% (placebo 6.7%) diarrhoea 16.5% (placebo 7.8%) headache 14.2% (placebo 11.2%) NCT01557166 · Phase 3 · monotherapy · Obesity · phase 3 3.0 mg nausea 42.4% (placebo 14.3%) vomiting 34.4% (placebo 4%) nasopharyngitis 27.2% (placebo 30.2%) NCT02918279 · Phase 3 3 mg nausea 41.9% gastrointestinal hypomotility 35.8% diarrhoea 27.7% NCT03036800 · Phase 4 · registry result, not featured evidence · combination nausea 23.6% (placebo 7%) constipation 15.7% (placebo 9.3%) abdominal pain 9% (placebo 2.3%) NCT03048578 · Phase 4 · registry result, not featured evidence 3.0 mg gi related 46.7% (placebo 12.9%) respiratory tract infection 10.9% (placebo 15.1%) injection site reaction 7.6% (placebo 8.6%) NCT03038620 · Phase 4 · registry result, not featured evidence nausea 36% (placebo 4.3%) upper respiratory infection 32% (placebo 8.7%) constipation 30% (placebo 0%) NCT02911818 · Phase 4 · registry result, not featured evidence nausea 25% (placebo 25%) NCT01562678 · Phase 4 · registry result, not featured evidence nausea 16.7% (placebo 11.1%) vomiting 16.7% (placebo 11.1%) hgb < 11.5 g/dl 0% (placebo 0%) NCT03115424 · Phase 3 · registry result, not featured evidence during study 24.7% (placebo 25%) NCT03374956 · Phase 3 · registry result, not featured evidence · Obesity · phase 3 3 mg nausea 25.5% (placebo 11.1%) vomiting 9.1% (placebo 0%) diarrhea 7.3% (placebo 0%) NCT03480022 · Phase 3 · registry result, not featured evidence diarrhoea 50% (placebo 16.7%) abdominal pain 30% (placebo 25%) constipation 15% (placebo 0%) NCT02527200 · Phase 3 · registry result, not featured evidence diarrhoea 41.2% (placebo 16.7%) abdominal pain 17.6% (placebo 25%) abdominal pain upper 17.6% (placebo 0%) NCT02527200 · Phase 3 · registry result, not featured evidence 3.0 mg nausea 29.7% (placebo 11.7%) diarrhoea 23.1% (placebo 15.2%) nasopharyngitis 21.5% (placebo 18.3%) NCT02963922 · Phase 3 · registry result, not featured evidence 3.0 mg nausea 47.9% (placebo 17.9%) constipation 30.3% (placebo 18.6%) vomiting 23.2% (placebo 5%) NCT02963935 · Phase 3 · registry result, not featured evidence elective back surgery 2.9% (placebo 0%) family issues 2.9% (placebo 0%) protocol deviation 2.9% (placebo 0%) NCT01784965 · Phase 3 · registry result, not featured evidence dyspepsia 23.5% constipation 11.8% fatigue 11.8% NCT04883346 · Phase 2 · registry result, not featured evidence nausea 65.5% (placebo 45.2%) constipation 41.4% (placebo 9.7%) heartburn 34.5% (placebo 6.5%) NCT03158805 · Phase 2 · registry result, not featured evidence nausea 59.7% (placebo 15.9%) diarrhea 34.3% (placebo 8.7%) abdominal pain/discomfort 28.4% (placebo 5.8%) NCT03523273 · Phase 2 · registry result, not featured evidence nausea 63.2% (placebo 9.5%) headache 26.3% (placebo 19%) abdominal pain/discomfort 21.1% (placebo 9.5%) NCT02647944 · Phase 2 · registry result, not featured evidence 3.0 mg nausea 50.5% nasopharyngitis 40.9% headache 23.7% NCT00422058 · Phase 2 · registry result, not featured evidence 1.8 mg / 3.0 mg nasopharyngitis 37.8% nausea 37.8% gastroenteritis 22.2% NCT00422058 · Phase 2 · registry result, not featured evidence 2.4 mg / 3.0 mg nasopharyngitis 45.2% nausea 41.9% headache 24.7% NCT00422058 · Phase 2 · registry result, not featured evidence placebo / 2.4 mg / 3.0 mg nasopharyngitis 41.8% nausea 29.6% headache 23.5% NCT00422058 · Phase 2 · registry result, not featured evidence 1.2 mg / 3.0 mg nasopharyngitis 38.9% nausea 36.8% influenza 25.3% NCT00422058 · Phase 2 · registry result, not featured evidence 420 mg abdominal pain 0% (placebo 0%) arthralgia 0% (placebo 0%) back pain 0% (placebo 0%) NCT03757130 · Phase 1 · registry result, not featured evidence nausea 50% (placebo 0%) diarrhoea 33.3% (placebo 0%) upper respiratory tract infection 33.3% (placebo 16.7%) NCT03757130 · Phase 1 · registry result, not featured evidence · combination 210 mg upper respiratory tract infection 50% (placebo 16.7%) arthralgia 16.7% (placebo 0%) blood creatine phosphokinase increased 16.7% (placebo 0%) NCT03757130 · Phase 1 · registry result, not featured evidence upper respiratory tract infection 66.7% (placebo 16.7%) constipation 33.3% (placebo 0%) early satiety 33.3% (placebo 0%) NCT03757130 · Phase 1 · registry result, not featured evidence · combination 70 mg back pain 16.7% (placebo 0%) constipation 16.7% (placebo 0%) diarrhoea 16.7% (placebo 0%) NCT03757130 · Phase 1 · registry result, not featured evidence decreased appetite 62.5% (placebo 0%) lipase increased 37.5% (placebo 0%) nausea 25% (placebo 0%) NCT03757130 · Phase 1 · registry result, not featured evidence · combination nausea 46.9% (placebo 3.6%) diarrhoea 34.4% (placebo 14.3%) headache 34.4% (placebo 10.7%) NCT03041792 · Phase 1 · registry result, not featured evidence | 2.4 mg weeklyu nausea 44.1% (placebo 17.4%) diarrhoea 31.5% (placebo 15.9%) vomiting 24.6% (placebo 6.6%) NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 show 35 more results2.4 mg diarrhoea 14.4% (placebo 7.1%) nausea 14% (placebo 4.9%) constipation 11.6% (placebo 6%) NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 2.4 mg nausea 33.5% (placebo 9.2%) diarrhoea 21.3% (placebo 11.9%) vomiting 21.3% (placebo 2.7%) NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 covid-19 20.3% (placebo 20.3%) nausea 18.1% (placebo 3.8%) diarrhoea 10.6% (placebo 4%) NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3 2.4 mg nausea 58.2% (placebo 22.1%) constipation 36.9% (placebo 24.5%) diarrhoea 36.1% (placebo 22.1%) NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 nausea 73.6% (placebo 25%) constipation 52.8% (placebo 16.7%) diarrhea 37.5% (placebo 22.9%) NCT05548647 · Phase 4 · registry result, not featured evidence · combination diarrhea 20% (placebo 22.9%) constipation 10% (placebo 16.7%) eructation 10% (placebo 6.3%) NCT05548647 · Phase 4 · registry result, not featured evidence 2.4 mg decreased appetite 19.3% (placebo 2.5%) diarrhoea 18.6% (placebo 7.4%) nausea 18% (placebo 2.5%) NCT06041217 · Phase 3 · registry result, not featured evidence 7.2 mg nausea 43.7% (placebo 13.4%) diarrhoea 27.3% (placebo 12.9%) vomiting 24.8% (placebo 7%) NCT05646706 · Phase 3 · registry result, not featured evidence nausea 37.6% (placebo 14.3%) diarrhoea 27.7% (placebo 6.1%) constipation 21.8% (placebo 16.3%) NCT04998136 · Phase 3 · registry result, not featured evidence 2.4 mg nausea 21.9% (placebo 8.9%) covid-19 18.6% (placebo 22.2%) constipation 11.9% (placebo 5.2%) NCT05064735 · Phase 3 · registry result, not featured evidence 2.4 mg covid-19 34.8% (placebo 30.4%) nausea 29% (placebo 4.3%) constipation 18.1% (placebo 0%) NCT05040971 · Phase 3 · registry result, not featured evidence 2.4 mg nausea 17.1% (placebo 2.6%) covid-19 13.7% (placebo 15.4%) diarrhoea 9.1% (placebo 3.8%) NCT04788511 · Phase 3 · registry result, not featured evidence 2.4 mg diarrhoea 26.1% (placebo 10.3%) nausea 24.1% (placebo 7.1%) upper respiratory tract infection 20.5% (placebo 20.6%) NCT04251156 · Phase 3 · registry result, not featured evidence 2.4 mg nausea 42.1% (placebo 17.9%) vomiting 36.1% (placebo 10.4%) diarrhoea 21.8% (placebo 19.4%) NCT04102189 · Phase 3 · registry result, not featured evidence 2.4 mg nausea 61.1% (placebo 22.4%) constipation 38.9% (placebo 23.5%) diarrhoea 27.8% (placebo 25.9%) NCT04074161 · Phase 3 · registry result, not featured evidence 2.4 mg nausea 53.3% (placebo 21.7%) diarrhoea 34.9% (placebo 23.7%) constipation 30.9% (placebo 11.2%) NCT03693430 · Phase 3 · registry result, not featured evidence 2.4 mg nasopharyngitis 26.6% (placebo 17.8%) constipation 26.1% (placebo 3%) nausea 17.6% (placebo 4%) NCT03811574 · Phase 3 · registry result, not featured evidence 1.7 mg nasopharyngitis 24% (placebo 17.8%) diarrhoea 22% (placebo 5.9%) constipation 19% (placebo 3%) NCT03811574 · Phase 3 · registry result, not featured evidence 30 mg/kg + 1.0 mg muscle spasms 64.3% acne 55.4% diarrhoea 44.6% NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 30 mg/kg + 2.4 mg muscle spasms 63.6% acne 52.7% diarrhoea 49.1% NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 10 mg/kg + 1.0 mg muscle spasms 57.1% diarrhoea 48.2% acne 42.9% NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 10 mg/kg + 2.4 mg muscle spasms 65.5% nausea 61.8% diarrhoea 52.7% NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 gastrointestinal side effects: constipation 57.1% gi side effects: nausea 28.6% gi side effects: vomiting 14.3% NCT05302596 · Phase 2 · registry result, not featured evidence 2.0 mg + 2.4 mg decreased appetite 87.5% (placebo 75%) nausea 87.5% (placebo 12.5%) vomiting 75% (placebo 0%) NCT04969939 · Phase 2 · registry result, not featured evidence · combination 2.0 mg + 2.4 mg nausea 62.5% (placebo 12.5%) constipation 50% (placebo 0%) vomiting 37.5% (placebo 0%) NCT04969939 · Phase 2 · registry result, not featured evidence · combination 1.0 mg + 2.4 mg decreased appetite 87.5% (placebo 75%) nausea 50% (placebo 12.5%) abdominal pain 37.5% (placebo 0%) NCT04969939 · Phase 2 · registry result, not featured evidence · combination 1.0 mg + 2.4 mg nausea 44.7% (placebo 12.5%) vomiting 31.9% (placebo 0%) constipation 25.5% (placebo 0%) NCT04969939 · Phase 2 · registry result, not featured evidence · combination 0.4 mg nausea 48% (placebo 17.6%) diarrhoea 37.3% (placebo 11.8%) constipation 23.5% (placebo 4.4%) NCT02453711 · Phase 2 · registry result, not featured evidence 0.4 mg (Fast Escalation) nausea 48.5% (placebo 17.6%) constipation 28.2% (placebo 4.4%) diarrhoea 27.2% (placebo 11.8%) NCT02453711 · Phase 2 · registry result, not featured evidence 0.3 mg nausea 41.7% (placebo 17.6%) diarrhoea 26.2% (placebo 11.8%) constipation 17.5% (placebo 4.4%) NCT02453711 · Phase 2 · registry result, not featured evidence 0.3 mg (Fast Escalation) nausea 53.9% (placebo 17.6%) diarrhoea 27.5% (placebo 11.8%) vomiting 20.6% (placebo 4.4%) NCT02453711 · Phase 2 · registry result, not featured evidence 0.2 mg nausea 43.7% (placebo 17.6%) diarrhoea 34% (placebo 11.8%) constipation 25.2% (placebo 4.4%) NCT02453711 · Phase 2 · registry result, not featured evidence 0.1 mg nausea 41.2% (placebo 17.6%) diarrhoea 24.5% (placebo 11.8%) nasopharyngitis 22.5% (placebo 11.8%) NCT02453711 · Phase 2 · registry result, not featured evidence 0.05 mg nausea 31.1% (placebo 17.6%) diarrhoea 19.4% (placebo 11.8%) nasopharyngitis 15.5% (placebo 11.8%) NCT02453711 · Phase 2 · registry result, not featured evidence nausea 58.3% (placebo 20.8%) abdominal pain 31.3% (placebo 20.8%) diarrhea 29.2% (placebo 10.4%) NCT04779697 · Phase 1 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation context differs: registered conditions differ.
- cPopulation context differs: registered conditions differ; age eligibility differs (includes children versus adolescents and adults).
- dAssessment timepoints differ: 52 weeks versus 68 weeks.
- ePopulation comparability has not been reviewed for both studies.
- fTreatment context has not been resolved for both arms.
- gAssessment timepoints differ: 56 weeks versus 68 weeks.
- hTrial phases differ: Phase 3 versus Phase 2.
- iPopulation context differs: eligible sex differs (FEMALE versus ALL).
- jAssessment timepoints differ: 32 weeks versus 72 weeks.
- kTrial phases differ: Phase 4 versus Phase 2.
- lAssessment timepoints differ: 40 weeks versus 52 weeks.
- mAssessment timepoints differ: 56 weeks versus 104 weeks.
- nAssessment timepoints differ: 104 weeks versus 48 weeks.
- oTrial phases differ: Phase 2 versus Phase 3.
- pAssessment timepoints differ: 52 weeks versus 104 weeks.
- qThe reported result categories differ.
- rAssessment timepoints differ: 40 weeks versus 72 weeks.
- sAssessment timepoints differ: 52 weeks versus 72 weeks.
- tAssessment timepoints differ: 32 weeks versus 104 weeks.
- uPopulation comparability has not been reviewed for 30 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Liraglutide (Saxenda)
show 1 more result
show 1 more result
show 1 more result
show 6 more results
show 1 more result
+ 160 further endpoints in the CSV export.
Semaglutide (Wegovy)
show 3 more results
show 13 more results
show 13 more results
show 2 more results
+ 117 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Liraglutide (Saxenda)'s landscape · Semaglutide (Wegovy)'s landscape